Study to Compare Efficacy and Safety of CT-P42 in Comparison With Eylea in Patients With Diabetic Macular Edema
Phase 3
Completed
NCT04739306
| Condition | Diabetic Macular Edema |
|---|
| Phase | Phase 3 |
|---|
| Sponsor | Celltrion |
|---|
| Status | Completed |
|---|
| Enrollment | 348 participants |
|---|
| Interventions | CT-P42, Eylea |
|---|
| Start date | Jul 22, 2021 |
|---|
| Completion date | Oct 14, 2022 |
|---|
| Results posted | Dec 5, 2023 |
|---|
Summary
This is a Randomized, Active-Controlled, Double-Masked, Parallel-Group, Phase 3 Study to Compare Efficacy and Safety of CT-P42 in comparison with Eylea in Patients with Diabetic Macular Edema
Mean Change From Baseline in Best Corrected Visual Acuity (BCVA) at Week 8
Baseline and Week 8 · letters
| CT-P42 | 9.43 ± 0.798 letters |
|---|
| Eylea | 8.85 ± 0.775 letters |
|---|
| Estimated difference in LS means | 0.58 (95% CI -0.52–1.67) |
|---|
Open in BENITIONS
View on ClinicalTrials.gov
All trials
This page summarises publicly available data from ClinicalTrials.gov. It is not medical advice and not investment advice. Always consult a qualified healthcare professional.